Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer

被引：14
|
作者：
Tone, Mari [1 ]
Izumo, Takehiro [1 ]
Awano, Nobuyasu [1 ]
Kuse, Naoyuki [1 ]
Inomata, Minoru [1 ]
Jo, Tatsunori [1 ]
Yoshimura, Hanako [1 ]
Miyamoto, Shingo [2 ]
Kunitoh, Hideo [2 ]
机构：
[1] Japanese Red Cross Med Ctr, Dept Resp Med, Shibuya Ku, Tokyo, Japan
[2] Japanese Red Cross Med Ctr, Dept Med Oncol, Shibuya Ku, Tokyo, Japan
来源：
LUNG CANCER MANAGEMENT | 2019年 / 8卷 / 02期
关键词：
immune checkpoint inhibitor; NSCLC; salvage chemotherapy; RANDOMIZED PHASE-III; RESPONSE RATES; DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; VINORELBINE; CARBOPLATIN; TRIAL; CELLS;
D O I：
10.2217/lmt-2019-0001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Aim: To assess the relationship of treatment effects between immune checkpoint inhibitor (ICI) and salvage chemotherapy, with the safety profile of salvage chemotherapy. Patients & methods: 18 patients with advanced NSCLC treated using salvage chemotherapy following ICI treatment were retrospectively included. We assessed the overall response rate to and adverse events of salvage chemotherapy. Results: The overall response rate to salvage chemotherapy was 33.3% and that of ICI responders was significantly higher than that of ICI nonresponders (66.7 vs 16.7%, respectively, p = 0.03). The incidence rate of adverse events to salvage chemotherapy was 55.6%. Conclusion: The efficacy of salvage chemotherapy was similar to that preceding ICI. Moreover, the safety of salvage chemotherapy was good.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer
    Cabezas-Camarero, Santiago
    Nieves Cabrera-Martin, Maria
    Merino-Menendez, Salome
    Paz-Cabezas, Mateo
    Garcia-Barberan, Vanesa
    Saiz-Pardo Sanz, Melchor
    Iglesias-Moreno, Maricruz
    Alonso-Ovies, Almudena
    Perez-Segura, Pedro
    ONCOLOGIST, 2021, 26 (06): : E1018 - E1035
  • [32] Safety and Efficacy of Salvage Surgery after Treatment With Immune-Checkpoint Adjuvant Inhibitors for Advanced Non-Small Cell Lung Cancer: A Multicentric Study
    Schiavon, Marco
    Cannone, Giorgio
    Bertolaccini, Luca
    Gallina, Filippo Tommaso
    Pezzuto, Federica
    Lorenzoni, Giulia
    Facciolo, Francesco
    Spaggiari, Lorenzo
    Calabrese, Fiorella
    Rea, Federico
    Pasello, Giulia
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [33] Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
    Liao, Juan-Yan
    Zhang, Shuang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors
    Ichiki, Yoshinobu
    Fukuyama, Takashi
    Ueno, Mari
    Kanasaki, Yoshiro
    Goto, Hidenori
    Takahashi, Mai
    Mikami, Shuji
    Kobayashi, Noritada
    Nakanishi, Kozo
    Hayashi, Shinichi
    Ishida, Tsuyoshi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 2192 - 2207
  • [35] Tolerability and Safety of Thoracic Radiation and Immune Checkpoint Inhibitors Among Patients with Lung Cancer
    Ahmed, K. A.
    Grass, G. D.
    Creelan, B.
    Gray, J.
    Kim, S.
    Dilling, T. J.
    Antonia, S. J.
    Perez, B. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 224 - 224
  • [36] Safety of current immune checkpoint inhibitors in non-small cell lung cancer
    Abdayem, Pamela
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 651 - 667
  • [37] Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer
    Wang, Shuai
    Hao, Jiatao
    Wang, Hao
    Fang, Yong
    Tan, Lijie
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [38] Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
    Iuchi, T.
    Ashinuma, H.
    Yoshida, Y.
    Mizuno, S.
    Hosono, J.
    Setoguchi, T.
    Hasegawa, Y.
    Sakaida, T.
    Shingyoji, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 622 - 622
  • [39] Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
    Passaro, Antonio
    Brahmer, Julie
    Antonia, Scott
    Mok, Tony
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06) : 598 - +
  • [40] Immune checkpoint inhibitors:breakthroughs in cancer treatment
    Xueqing Kong
    Jinyi Zhang
    Shuwei Chen
    Xianyang Wang
    Qing Xi
    Han Shen
    Rongxin Zhang
    Cancer Biology & Medicine, 2024, (06) : 451 - 472
12345